Memantine is an antagonist of the N-Methyl-D-aspartate (NMDA) receptor. It's a prescription medicine that's used to treat Alzheimer's disease-related dementia (confusion).
The rise in research and development efforts, as well as the emergence of new markets, will benefit the Memantine Market in the projected period of 2022-2029. However, there is a significant cost connected with memantine, as well as adverse effects such as headache, nausea, vomiting, dizziness, anxiety, seizures, and others. All of these obstacles stifle market expansion. During the projection period, the memantine market will face additional challenges due to a lack of knowledge and an increase in the number of drug patents that have expired.
Read more @ https://creativeedge16.blogspot.com/2022/02/memantine-market-remarking-enormous.html
